Correlation between anti-infliximab trough level and clinical markers in ulcerative colitis patients treated with infliximab

Correlation between anti-infliximab trough level and clinical markers in ulcerative colitis patients treated with infliximab - IFX trough level in UC patients

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000037953

Enrollment

Registered

2019-09-09

Start date

2017-02-07

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ulcerative colitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: ulcerative colitis patients treated with infliximab

Exclusion criteria

Exclusion criteria: patients with allergy to infliximab patients with severe cardiovascular disease treated with anticoagulant medications patients suspected colonic cancer patinent with severe infectious disease through blood

Design outcomes

Primary

Measure	Time frame
time for clinical and endoscopic recurrence	—

Secondary

Measure	Time frame
factors associated with anti-infliximab trough levels	—

Countries

Japan

Contacts

Public ContactHiroki Tanabe

Asahikawa Medical University Department of Medicine

tant@asahikawa-med.ac.jp+81-166-68-2462

Outcome results